Published in J Hepatol on October 01, 2000
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology (2013) 1.58
Primary biliary cirrhosis. Semin Immunopathol (2009) 1.46
Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol (2008) 1.25
Overlap syndromes among autoimmune liver diseases. World J Gastroenterol (2008) 1.21
Primary sclerosing cholangitis. Can J Gastroenterol (2008) 1.17
Primary sclerosing cholangitis: updates in diagnosis and therapy. World J Gastroenterol (2005) 1.16
Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management. Hepatol Int (2010) 1.05
The revised international autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis/overlap syndromes and autoimmune hepatitis with concurrent other liver disorders. J Autoimmune Dis (2007) 1.02
Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol (2013) 0.98
Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut (2002) 0.89
Management of primary sclerosing cholangitis: conventions and controversies. Can J Gastroenterol (2012) 0.86
Comparing the simplified and international autoimmune hepatitis group criteria in primary sclerosing cholangitis. Gastroenterol Hepatol (N Y) (2010) 0.85
Validation and modification of simplified diagnostic criteria for autoimmune hepatitis in children. Clin Gastroenterol Hepatol (2011) 0.85
Clinical significance of immunoglobulin G4-associated autoimmune hepatitis. J Gastroenterol (2010) 0.84
Cirrhosis and autoimmune liver disease: Current understanding. World J Hepatol (2016) 0.81
Overlap syndromes: an emerging diagnostic and therapeutic challenge. Saudi J Gastroenterol (2014) 0.78
Small duct autoimmune sclerosing cholangitis and Crohn colitis in a 10-year-old child. A case report and review of the literature. Diagn Pathol (2012) 0.78
Overlap of primary biliary cirrhosis and primary sclerosing cholangitis - a rare coincidence or a new syndrome. Int J Gen Med (2010) 0.78
Risk and Surveillance of Cancers in Primary Biliary Tract Disease. Gastroenterol Res Pract (2016) 0.78
Diagnosis of primary sclerosing cholangitis--autoimmune hepatitis overlap syndrome: to score or not to score? J Hepatol (2000) 0.78
Overlap syndrome consisting of PSC-AIH with concomitant presence of a membranous glomerulonephritis and ulcerative colitis. World J Gastroenterol (2014) 0.76
Genetics of primary sclerosing cholangitis and pathophysiological implications. Nat Rev Gastroenterol Hepatol (2017) 0.75
Criteria Used in Clinical Practice to Guide Immunosuppressive Treatment in Patients with Primary Sclerosing Cholangitis. PLoS One (2015) 0.75
Two Cases of Primary Sclerosing Cholangitis Overlapping with Autoimmune Hepatitis in Adults. Intern Med (2017) 0.75
Evaluating distinctive features for early diagnosis of primary sclerosing cholangitis overlap syndrome in adults with autoimmune hepatitis. Ulster Med J (2011) 0.75
Is there any association between non-Hodgkin's lymphoma and primary sclerosing cholangitis/autoimmune hepatitis overlap syndrome? Dig Dis Sci (2007) 0.75
Differences in Phenotypes and Liver Transplantation Outcomes by Age Group in Patients with Primary Sclerosing Cholangitis. Dig Dis Sci (2017) 0.75
Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology (1999) 5.75
The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut (2009) 4.01
Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med (1993) 3.83
High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol (2001) 2.61
Unsedated small-caliber esophagogastroduodenoscopy (EGD) versus conventional EGD: a comparative study. Gastroenterology (1999) 2.44
GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther (2007) 2.41
The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol (1999) 2.18
Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol (2001) 2.11
Cost-effectiveness of ultrasound-guided liver biopsy. Hepatology (1998) 2.06
Variant forms of cholestatic diseases involving small bile ducts in adults. Am J Gastroenterol (2000) 1.83
A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N Engl J Med (1990) 1.81
Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther (2013) 1.79
Dysphagia without endoscopically evident disease: to dilate or not? Am J Gastroenterol (2001) 1.76
Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study. Gastroenterology (1990) 1.76
Magnetic resonance cholangiography in patients with biliary disease: its role in primary sclerosing cholangitis. J Hepatol (2000) 1.70
Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. Dig Dis Sci (2001) 1.65
Treatment of non-alcoholic fatty liver disease. Postgrad Med J (2006) 1.63
Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology (1997) 1.63
Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology (1996) 1.62
Immunohistochemical characterization of hepatic lymphocytes in primary biliary cirrhosis in comparison with primary sclerosing cholangitis and autoimmune chronic active hepatitis. Mayo Clin Proc (1993) 1.59
Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology (2000) 1.55
Recent concepts in non-alcoholic fatty liver disease. Diabet Med (2005) 1.54
Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis. Hepatology (1999) 1.54
Primary sclerosing cholangitis. Hepatology (1999) 1.52
High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Aliment Pharmacol Ther (2011) 1.52
Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis. Mayo Clin Proc (1994) 1.47
A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc (2000) 1.45
Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis. Liver Transpl Surg (1999) 1.41
The role of portosystemic shunts for variceal bleeding in the liver transplantation era. Arch Surg (1994) 1.40
Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol (2001) 1.24
Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J Hepatol (2001) 1.24
Review: nonalcoholic steatohepatitis. J Gastroenterol Hepatol (1997) 1.14
Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol (2001) 1.12
Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol (2001) 1.12
Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology (2000) 1.08
Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk? Hepatology (1992) 1.08
Balloon dilatation of upper digestive tract strictures. Gastroenterology (1985) 1.08
Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology (1999) 1.07
Methotrexate in the treatment of primary biliary cirrhosis: the hype and the hope. Gastroenterology (1999) 1.07
Antimitochondrial antibody-negative primary biliary cirrhosis. Am J Gastroenterol (1995) 1.05
The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology (1999) 1.05
Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study. Dig Dis Sci (1999) 1.05
Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology (2000) 1.03
Incidence of cancer in primary biliary cirrhosis: the Mayo experience. Hepatology (1999) 1.02
Oral budesonide in the treatment of primary sclerosing cholangitis. Am J Gastroenterol (2000) 1.02
A randomized prospective study comparing rigid to balloon dilators for benign esophageal strictures and rings. Gastrointest Endosc (1999) 1.01
Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology (1999) 1.01
Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol (2000) 0.99
Time course of histological progression in primary biliary cirrhosis. Hepatology (1996) 0.98
Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. J Hepatol (1998) 0.98
Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver (1999) 0.96
Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol (1995) 0.96
Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology (2000) 0.96
Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin Liver Dis (2001) 0.95
The metabolic bone disease of primary sclerosing cholangitis. Hepatology (1991) 0.95
An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities. Am J Gastroenterol (2000) 0.95
Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol (1999) 0.94
Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology (2000) 0.93
Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression. Hepatology (1997) 0.92
Lymphocyte subsets in primary sclerosing cholangitis. Dig Dis Sci (1987) 0.91
Interactions between chronic liver disease and inflammatory bowel disease. Inflamm Bowel Dis (1997) 0.91
Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. Am J Gastroenterol (2001) 0.90
Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Hepatology (1999) 0.89
Primary biliary cirrhosis and primary sclerosing cholangitis. Clin Liver Dis (1999) 0.88
Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. J Clin Gastroenterol (1995) 0.88
Adjuvant cholylsarcosine during ursodeoxycholic acid treatment of primary biliary cirrhosis. Dig Dis Sci (1998) 0.87
Current therapies for nonalcoholic fatty liver disease. Drugs Today (Barc) (2011) 0.86
Clinical trial: randomized controlled study of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. Aliment Pharmacol Ther (2008) 0.86
Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation. Hepatology (1997) 0.86
Natural history and prognostic models in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol (2001) 0.85
The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther (2011) 0.84
Editorial: Betaretrovirus in biliary epithelia of patients with autoimmune and cryptogenic liver disease. Aliment Pharmacol Ther (2015) 0.84
Methionine-enkephalin concentrations correlate with stage of disease but not pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol (1994) 0.84
Characterisation of patients with a complete biochemical response to ursodeoxycholic acid. Gut (1995) 0.84
Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am J Gastroenterol (1994) 0.84
Liver function values in adults receiving total parenteral nutrition. JAMA (1979) 0.83
A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am J Gastroenterol (2000) 0.83
Reliability and validity of the NIDDK-QA instrument in the assessment of quality of life in ambulatory patients with cholestatic liver disease. Hepatology (2000) 0.83
Increased intracranial pressure and hepatic encephalopathy in chronic liver disease. Am J Gastroenterol (1992) 0.82
Recurrent primary biliary cirrhosis after liver transplantation. Am J Transplant (2010) 0.82
Ursodeoxycholic acid for primary biliary cirrhosis. Lancet (2000) 0.82
High-volume postobstructive choleresis after transhepatic external biliary drainage resolves with conversion to internal drainage. J Clin Gastroenterol (1993) 0.81
Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: the Mayo Clinic experience. Am J Gastroenterol (2001) 0.81
The diagnostic and predictive value of ascites nitric oxide levels in patients with spontaneous bacterial peritonitis. Hepatology (1998) 0.81
Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile? Am J Gastroenterol (2001) 0.80
The natural history of abdominal pain associated with primary biliary cirrhosis. Am J Gastroenterol (1994) 0.80
Insulin resistance and mitochondrial abnormalities in NASH: a cool look into a burning issue. Gastroenterology (2001) 0.80
[Cor triatriatum with interventricular communication: Doppler color ultrasonography and magnetic resonance diagnosis. Repair in the first months]. Rev Esp Cardiol (1997) 0.80
Clinical and statistical analyses of new and evolving therapies for primary biliary cirrhosis. Hepatology (1988) 0.79
Paroxysmal nocturnal hemoglobinuria presenting as acute renal failure. Nephron (1984) 0.79
Cetirizine-induce cholestasis. J Clin Gastroenterol (2000) 0.79